Combination of TRAIL with Bortezomib Shifted Apoptotic Signaling from DR4 to DR5 Death Receptor by Selective Internalization and Degradation of DR4

Ubiquitination by the Membrane-associated RING-CH-8 (MARCH-8) Ligase Controls Steady-state Cell Surface Expression of Tumor Necrosis Factor-related Apoptosis Inducing Ligand (TRAIL) Receptor 1

(2013) Bert van de Kooij et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Delivery of sTRAIL variants by MSCs in combination with cytotoxic drug treatment leads to p53-independent enhanced antitumor effects

(2013) R Yu et al.   Cell Death & Disease

Bortezomib and TRAIL: A perfect match for apoptotic elimination of tumour cells?

(2012) L.H.A.M. de Wilt et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Distinct TRAIL Resistance Mechanisms Can Be Overcome by Proteasome Inhibition but not Generally by Synergizing Agents

(2011) C. Menke et al.   CANCER RESEARCH

Strategy for improvement of enteropeptidase efficiency in tag removal processes

(2011) Marine E. Gasparian et al.   PROTEIN EXPRESSION AND PURIFICATION

Modulation of death receptors by cancer therapeutic agents

(2010) Heath A. Elrod et al.   CANCER BIOLOGY & THERAPY

Cancer cell sensitivity to bortezomib is associated with survivin and p53 status but not cancer cell types

(2010) Xiang Linf et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Bortezomib Sensitizes Human Esophageal Squamous Cell Carcinoma Cells to TRAIL-Mediated Apoptosis via Activation of Both Extrinsic and Intrinsic Apoptosis Pathways

(2010) N. Seki et al.   MOLECULAR CANCER THERAPEUTICS

Generation of new TRAIL mutants DR5-A and DR5-B with improved selectivity to death receptor 5

(2009) Marine E. Gasparian et al.   APOPTOSIS

Mapatumumab and lexatumumab induce apoptosis in TRAIL-R1 and TRAIL-R2 antibody-resistant NSCLC cell lines when treated in combination with bortezomib

(2009) T. A. Luster et al.   MOLECULAR CANCER THERAPEUTICS

Cathepsins: Key modulators of cell death and inflammatory responses

(2008) Sébastien Conus et al.   BIOCHEMICAL PHARMACOLOGY

TRAIL receptor signalling and modulation: Are we on the right TRAIL?

(2008) Devalingam Mahalingam et al.   CANCER TREATMENT REVIEWS